Mark Breidenbach

Stock Analyst at Oppenheimer

(2.97)
# 2,419
Out of 4,497 analysts
52
Total ratings
35%
Success rate
3.25%
Average return
Main Sectors:
Top Industries:

16 Stocks

Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14$13
Current: $2.83
Upside: +359.36%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $5.14
Upside: +230.74%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $28.52
Upside: +233.10%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.11
Upside: +2,152.25%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.76
Upside: +1,213.54%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $1.23
Upside: +879.59%
Nurix Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $25
Current: $20.78
Upside: +20.31%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.83
Upside: +381.93%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8$7
Current: $1.82
Upside: +284.62%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36$32
Current: $2.29
Upside: +1,297.38%
Syros Pharmaceuticals
Mar 3, 2023
Maintains: Outperform
Price Target: $15$13
Current: $6.27
Upside: +107.34%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25$15
Current: $7.96
Upside: +88.44%
Synlogic
Oct 18, 2022
Maintains: Outperform
Price Target: $90$120
Current: $1.55
Upside: +7,641.94%
Achilles Therapeutics
Apr 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.84
Upside: -
bluebird bio
Dec 13, 2019
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Mustang Bio
Dec 21, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.32
Upside: -